A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp

Daniel J Diekema; Shawn A Messer; Richard J Hollis; Linda Boyken; Shailesh Tendolkar; Jennifer Kroeger; Ronald N Jones; Michael A Pfaller

doi:10.1016/j.diagmicrobio.2008.11.001

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp

Diagn Microbiol Infect Dis. 2009 Feb;63(2):233-6. doi: 10.1016/j.diagmicrobio.2008.11.001. Epub 2008 Dec 12.

Authors

Daniel J Diekema¹, Shawn A Messer, Richard J Hollis, Linda Boyken, Shailesh Tendolkar, Jennifer Kroeger, Ronald N Jones, Michael A Pfaller

Affiliation

¹ Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA. daniel-diekema@uiowa.edu

PMID: 19070452
DOI: 10.1016/j.diagmicrobio.2008.11.001

Abstract

Voriconazole susceptibility testing was performed on 7191 Candida spp. from 78 centers worldwide between 2004 and 2007. Voriconazole was very active in vitro (MIC(50)/MIC(90), 0.008/0.25 microg/mL; 98% susceptible). In comparison to 5866 Candida spp. isolates collected during global surveillance from 1997 to 2001, there were no changes in voriconazole mean MIC or MIC distribution.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antifungal Agents / pharmacology*
Candida / drug effects*
Candida / isolation & purification
Candidiasis / drug therapy*
Candidiasis / epidemiology
Candidiasis / microbiology*
Drug Resistance, Fungal
Global Health
Humans
Microbial Sensitivity Tests
Population Surveillance
Pyrimidines / pharmacology*
Triazoles / pharmacology*
Voriconazole

Substances

Antifungal Agents
Pyrimidines
Triazoles
Voriconazole